Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 3Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 17Surveys and Questionnaires 15pembrolizumab 14Specimen Handling 10Radiotherapy 10Early Intervention, Educational 10Zoledronic Acid 9Interviews as Topic 9olaparib 8Standard of Care 8Psychiatric Rehabilitation 8Therapeutics 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Fulvestrant 7durvalumab 6Paclitaxel 6Nivolumab 6Methods 6Educational Status 6Carboplatin 6enzalutamide 5Trastuzumab 5Radiosurgery 5Exercise 5Cyclophosphamide 5palbociclib 4Taxes 4Sirolimus 4Letrozole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Folfox protocol × Breast × Clear all
NCT02009449 2024-11-15

IVY

Eli Lilly and Company

Phase 1 Completed
353 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡